£800,000 grant for optimization of novel antibiotics targeting multidrug-resistant tuberculosis. Newcastle, UK – September 11, 2019 – Demuris Limited, a company focused on the discovery and
Focused on the development of novel therapeutics for mitochondrial diseases. Newcastle, UK – 2 August 2019 – The Wellcome Centre for Mitochondrial Research (WCMR) at Newcastle
Demuris has secured a £342,160 grant from Innovate UK to continue the development of a novel class of antibiotics for the treatment of multi-drug resistant
By Tom Garmeson, BBC, 13 September 2019 https://www.bbc.com/future/article/20190912-the-desert-soil-that-could-fight-superbug-bacteria
The Newcastle Business Journal BY JONATHON MANNING May 6 2019 https://www.business-live.co.uk/enterprise/newcastles-demuris-secures-800000-grant-16900039
Poster presentation by Dr. Richard Lewis, Demuris Limited “An actinomycete derived natural product compound targeting FOXO transcription factors in acute myeloid leukaemia“ Alderley Park Conference
Pipeline update – Prof. Jeff Errington, CEO & Founder Alderley Park Conference Centre, Wednesday 12th February, 2020
The Biosphere
Draymans Way, Newcastle Helix
Newcastle upon Tyne
NE4 5BX, UK
© DEMURIS LIMITED 2020 All rights reserved | DEMURIS LIMITED IS REGISTERED IN ENGLAND, COMPANY NUMBER: 06255507
Website designed and developed by Tiny Planet Digital
